Results 91 to 100 of about 11,979 (257)

The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient

Cancer Gene Therapy
Colorectal cancer (CRC) is known to be resistant to immunotherapy. In our phase-I clinical trial, one patient achieved a 313-day prolonged response during the combined treatment of oncolytic virotherapy and immunotherapy.
Hangyu Zhang, Yiqing Ren, Feiyu Wang, Xiaoxuan Tu, Z. Tong, Lulu Liu, Yi Zheng, Peng Zhao, Jinlin Cheng, Jianwen Li, Weijia Fang, Xia Liu   +11 more
semanticscholar   +1 more source

High Level Production of Monoclonal Antibodies Using an Optimized Plant Expression System

Frontiers in Bioengineering and Biotechnology, 2020
Biopharmaceuticals are a large and fast-growing sector of the total pharmaceutical market with antibody-based therapeutics accounting for over 100 billion USD in sales yearly.
Andrew G. Diamos, Andrew G. Diamos, Joseph G. L. Hunter, Joseph G. L. Hunter, Mary D. Pardhe, Mary D. Pardhe, Sun H. Rosenthal, Sun H. Rosenthal, Haiyan Sun, Haiyan Sun, Bonnie C. Foster, Michelle P. DiPalma, Michelle P. DiPalma, Qiang Chen, Qiang Chen, Hugh S. Mason, Hugh S. Mason   +16 more
doaj   +1 more source

Impact of SPP1 and HMOX1 Genes in Glioma: Correlations With Oncolytic Virus Infection, Adverse Prognosis and Increased Cell Proliferation

Journal of Cellular and Molecular Medicine, Volume 29, Issue 11, June 2025.
ABSTRACT A high death rate among glioma patients is primarily due to poor prognostic outcomes and tumour metastasis. Oncolytic viruses have gained attention as a potential therapeutic strategy as eliminating tumour cells and modifying tumour microenvironment.
Chunze Cui, Chunyan Wu, Shaoqi Zhang, Xiaofeng Yin   +3 more
wiley   +1 more source

Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.

Journal of Clinical Investigation, 2021
Clinical immunotherapy approaches are lacking efficacy in the treatment of glioblastoma (GBM). In this study, we sought to reverse local and systemic GBM-induced immunosuppression using the Helicobacter pylori neutrophil-activating protein (NAP), a ...
E. Panagioti, C. Kurokawa, K. Viker, Arun Ammayappan, S. K. Anderson, S. Sotiriou, Kyriakos Chatzopoulos, K. Ayasoufi, Aaron J. Johnson, I. Iankov, E. Galanis   +10 more
semanticscholar   +1 more source

Current strategies in engaging oncolytic viruses with antitumor immunity

Molecular Therapy: Oncolytics, 2021
Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni, Divya Ravirala, Shaun Xiaoliu Zhang   +2 more
doaj  

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements

Cancer Medicine, Volume 14, Issue 9, May 2025.
ABSTRACT Background Triple‐negative breast cancer (TNBC) is one of the most heterogeneous and menacing forms of breast cancer, with no sustainable cure available in the current treatment landscape. Its lack of targets makes it highly unresponsive to various treatment modalities, which is why chemotherapy continues to be the primary form of treatment ...
Rachana Raman, Shristi Debata, Thirupugal Govindarajan, Praveen Kumar   +3 more
wiley   +1 more source

Oncolytic Virotherapy: From Bench to Bedside

Frontiers in Cell and Developmental Biology, 2021
Oncolytic viruses are naturally occurring or genetically engineered viruses that can replicate preferentially in tumor cells and inhibit tumor growth. These viruses have been considered an effective anticancer strategy in recent years.
Ludi Yang, X. Gu, Jie Yu, S. Ge, Xianqun Fan   +4 more
semanticscholar   +1 more source

Advancing ORFV‐Based Therapeutics to the Clinical Stage

Reviews in Medical Virology, Volume 35, Issue 3, May 2025.
ABSTRACT The Orf virus (ORFV) is the prototype member of the parapoxvirus family and has long been recognized for its robust immunogenicity, favourable safety profile and its ability to stimulate both cellular and humoural immune responses without inducing significant anti‐vector immunity.
Matthias Helmold, Ralf Amann
wiley   +1 more source

Ascites of patients with solid tumors shows distinct inflammatory patterns

Cancer Communications, EarlyView.
Julia M. Berger, Martin Korpan, Carina Zierfuss, Katharina Syböck, Erwin Tomasich, Andreas Kienzle, Maria Koenig, Markus Kleinberger, Lynn Gottmann, Birgit Fendl, Cihan Ay, Johannes Pammer, Catharina Müller, Rudolf Oehler, Lorenz Balcar, Thomas Reiberger, Elisabeth S. Bergen, Barbara Niederdorfer, Matthias Preusser, Anna S. Berghoff   +19 more
wiley   +1 more source

Oncolytic Virus Infection Modulates Lysine Acetyltransferase in Gliomas: Comprehensive Analysis and Experimental Validation of KAT8 in Glioma

Journal of Cellular and Molecular Medicine, Volume 29, Issue 8, April 2025.
ABSTRACT Oncolytic virotherapy, which uses engineered viruses to selectively target tumour cells, has emerged as a potential treatment in glioma. However, how oncolytic virus infection modulates lactylation enzymes in gliomas remains unclear. The RNA‐seq data after oncolytic virus EV‐A71 infection on glioma cells was analysed to screen and lysine ...
Xiaofeng Yin, Zhen Hao, Qi Liu, Rui Ding, Laizhao Chen, Mingliang Jin, Songquan Wang   +6 more
wiley   +1 more source